Cangrelor tetrasodium

Grey

Brand Name(s):Kengrexal

Indication:Thrombotic cardiovascular events in adult patients with coronary artery disease (reduction of)

Rationale:2

Considered:May-15

Review Date:Aug-20

Comments:
NICE technology appraisal guidance [TA351]

NICE is unable to make a recommendation about the use in the NHS of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy. Full information at: http://www.nice.org.uk/guidance/ta351/resources/guidance-cangrelor-for-reducing-atherothrombotic-events-in-people-undergoing-percutaneous-coronary-intervention-or-awaiting-surgery-requiring-interruption-of-antiplatelet-therapy-terminated-appraisal-pdf

July 2015